Treatment of Mood and Anxiety Disorders
AssigneeIcahn School of Medicine at Mount Sinai
InventorsDennis S Charney, James Murrough
Life of this patent
Estimating the term…
Abstract
As follows from the Background section, above, there is a need in the art for improved methods for the treatment of mood and/or anxiety disorders. The present disclosure provides therapeutic agents and methods for treating mood (e.g., Major Depressive Disorder) and anxiety disorders (e.g., OCD, PTSD). In certain aspects, the present disclosure provides a method for treating a human patient for a mood or anxiety disorder, which comprises intranasally administering to a human patient in need of such treatment a composition comprising a therapeutically effective amount of neuropeptide Y (NPY) for reducing or eliminating the symptoms (or one more of the symptoms) of the mood or anxiety disorder.
Claims31
A method for treating a human patient for a mood or anxiety disorder which comprises intranasally administering to a human patient in need of such treatment a composition comprising a therapeutically effective dose of neuropeptide Y (NPY) for reducing or eliminating one or more symptoms of the mood or anxiety disorder.
The method of any of the preceding claims, wherein the composition further comprises a pharmaceutically acceptable carrier.
A pharmaceutical formulation comprising:
- (a) at least about 0.005 mg/kg NPY and (b), a pharmaceutically acceptable carrier, wherein the pharmaceutical formulation is suitable for intranasal administration.
A pharmaceutical formulation comprising:
- (a) at least about 0.01 mg/kg NPY and (b), a pharmaceutically acceptable carrier, wherein the pharmaceutical formulation is suitable for intranasal administration.
A method for treating a human patient for a mood or anxiety disorder which comprises intranasally administering to a human patient in need of such treatment a composition comprising a therapeutically effective amount of a Y1 receptor agonist for reducing or eliminating the symptoms of the mood or anxiety disorder, wherein the therapeutically effective amount is a dosage range of about 0.005 milligrams per kilogram of body weight of the patient (mg/kg) to about 1 mg/kg.
A method for treating a human patient for a mood or anxiety disorder which comprises intranasally administering to a human patient in need of such treatment a composition comprising a therapeutically effective amount of a Y2 receptor antagonist for reducing or eliminating the symptoms of the mood or anxiety disorder, wherein the therapeutically effective amount is a dosage range of about 0.005 milligrams per kilogram of body weight of the patient (mg/kg) to about 1 mg/kg.
An intranasal dosage form comprising:
- (a) NPY and (b), a pharmaceutically acceptable diluent.
An aerosol formulation comprising NPY or an NPY analog and an aerosol propellant.
Dependencies are inferred from the claim text.